Fleischhacker W Wolfgang, Widschwendter Christian G
Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria.
Curr Opin Psychiatry. 2006 Mar;19(2):128-34. doi: 10.1097/01.yco.0000214336.21754.8c.
Although the debate on whether new antipsychotics have advantages over the old neuroleptics has recently been refueled by the first publication of the Clinical Antipsychotic Trials of Intervention Effectiveness results, one of the new challenges in the pharmacological management of schizophrenia patients is to choose among the new-generation drugs.
Earlier work has compared these medications primarily to traditional antipsychotics and until very recently there was little published information on the relative efficacy/safety of new-generation antipsychotics.
This review covers studies wherein therapeutic effects and adverse events of these drugs in schizophrenia patients were compared in head-to-head studies and that were published in 2005. Information is clearly more homogenous on the safety profile side, while the available evidence still offers little help for the clinicians' daily struggles to find the optimally effective antipsychotic for an individual schizophrenia patient.
尽管关于新型抗精神病药物是否优于传统抗精神病药物的争论因《临床抗精神病药物干预有效性试验》结果的首次发表而再度升温，但精神分裂症患者药物治疗管理中的新挑战之一是在新一代药物中进行选择。
早期研究主要将这些药物与传统抗精神病药物进行比较，直到最近，关于新一代抗精神病药物相对疗效/安全性的公开信息还很少。
本综述涵盖了2005年发表的、在头对头研究中比较这些药物对精神分裂症患者的治疗效果和不良事件的研究。在安全性方面，信息显然更为一致，而现有证据仍难以帮助临床医生在日常工作中为个体精神分裂症患者找到最佳有效的抗精神病药物。
